2016

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

View Abstract

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

View Abstract

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

View Abstract

2015

Kelsh MA, Chia VM. Historical comparator studies: Strengths, limitations, and analytical considerations in using historical pooled clinical data for evaluating efficacy and safety of new therapies. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Boston, MA, August 25, 2015.

Suh M, Mittal L, Hirsch S, Valdes R, Bartlett C, Rohr A, Proctor D. 2015. Lung cancer risk in chromate production workers exposed to hexavalent chromium. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

View Abstract

Wu E, Jensen IS, Cyr PL, Fan W, Mitchell M, Sulham K, Nathwani D. Use of oritavancin for the treatment of skin and soft tissue infections: A UK hospital budget impact analysis. ISPOR 20th Annual International Meeting, Philadelphia, PA, 2015.

Lancet JE, Cyr PL, Sacks NC, Chiarella MT, Louie AC, Cortes JE. CPX-351 enables administration of consolidation treatment in the outpatient setting and increases the time spent out of the hospital after completion of AML treatment compared with 7+3. American Society of Hematology Annual Meeting, San Diego CA, 2015.

2014

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10, ISPOR 17th Annual European Congress 2014.

View Abstract

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Taipei, Taiwan, October 28–30, 2014.